136 related articles for article (PubMed ID: 9134654)
1. Gender differences in platelet GPIIb-IIIa activation.
Faraday N; Goldschmidt-Clermont PJ; Bray PF
Thromb Haemost; 1997 Apr; 77(4):748-54. PubMed ID: 9134654
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry.
Faraday N; Goldschmidt-Clermont P; Dise K; Bray PF
J Lab Clin Med; 1994 May; 123(5):728-40. PubMed ID: 7515093
[TBL] [Abstract][Full Text] [Related]
3. Stimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb-IIIa.
Holme PA; Solum NO; Brosstad F; Egberg N; Lindahl TL
Thromb Haemost; 1995 Dec; 74(6):1533-40. PubMed ID: 8772233
[TBL] [Abstract][Full Text] [Related]
4. Platelets from bleeding Simmental cattle have a long delay in both ADP-activated expression of GpIIB-IIIA receptors and fibrinogen-dependent platelet aggregation.
Frojmovic MM; Wong T; Searcy GP
Thromb Haemost; 1996 Dec; 76(6):1047-52. PubMed ID: 8972030
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein specifically binds glycoprotein IIb/IIIa: a flow cytometric method for ligand-receptor interaction.
Tetik S; Uras F; Ekşioğlu-Demiralp E; Turay Yardimci K
Clin Appl Thromb Hemost; 2008 Apr; 14(2):210-9. PubMed ID: 18160616
[TBL] [Abstract][Full Text] [Related]
6. Combined defect in membrane expression and activation of platelet GPIIb--IIIa complex without primary sequence abnormalities in myeloproliferative disease.
Kaplan R; Gabbeta J; Sun L; Mao GF; Rao AK
Br J Haematol; 2000 Dec; 111(3):954-64. PubMed ID: 11122160
[TBL] [Abstract][Full Text] [Related]
7. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
[TBL] [Abstract][Full Text] [Related]
8. High shear stress attenuates agonist-induced, glycoprotein IIb/IIIa-mediated platelet aggregation when von Willebrand factor binding to glycoprotein Ib/IX is blocked.
Iijima K; Murata M; Nakamura K; Kitaguchi T; Handa M; Watanabe K; Fujimura Y; Yoshioka A; Ikeda Y
Biochem Biophys Res Commun; 1997 Apr; 233(3):796-800. PubMed ID: 9168936
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of PM6/13, a beta3-specific (GPIIIa/CD61) monoclonal antibody that shows preferential inhibition of fibrinogen binding over fibronectin binding to activated human platelets.
Patel Y; Rahman S; Siddiqua A; Wilkinson JM; Kakkar VV; Authi KS
Thromb Haemost; 1998 Jan; 79(1):177-85. PubMed ID: 9459345
[TBL] [Abstract][Full Text] [Related]
10. Characterization of human platelet IgG Fc receptor associated with membrane glycoprotein.
Shido K; Ahmad G; Hsu L; Kamiyama M
J Clin Lab Immunol; 1995; 46(1):1-11. PubMed ID: 9363587
[TBL] [Abstract][Full Text] [Related]
11. Shear stress-induced binding of von Willebrand factor to platelets.
Konstantopoulos K; Chow TW; Turner NA; Hellums JD; Moake JL
Biorheology; 1997; 34(1):57-71. PubMed ID: 9176590
[TBL] [Abstract][Full Text] [Related]
12. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor.
Xiao Z; Théroux P; Frojmovic M
Thromb Haemost; 1999 Feb; 81(2):281-5. PubMed ID: 10064007
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of fibrinogen binding and surface recruitment of GpIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852.
Wittig K; Rothe G; Schmitz G
Thromb Haemost; 1998 Mar; 79(3):625-30. PubMed ID: 9531053
[TBL] [Abstract][Full Text] [Related]
14. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
Chiang TM; Zhu J
Thromb Res; 2005; 115(6):503-8. PubMed ID: 15792682
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
Mousa SA; Bozarth JM; Lorelli W; Forsythe MS; Thoolen MJ; Slee AM; Reilly TM; Friedman PA
J Pharmacol Exp Ther; 1998 Sep; 286(3):1277-84. PubMed ID: 9732389
[TBL] [Abstract][Full Text] [Related]
16. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric analysis of the platelet surface area and surface density of glycoprotein IIb-IIIa of unactivated human platelets of various sizes.
Leytin V; Shapiro H; Novikov I; Radnay J
Biochem Biophys Res Commun; 1996 Sep; 226(1):94-100. PubMed ID: 8806597
[TBL] [Abstract][Full Text] [Related]
18. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
[TBL] [Abstract][Full Text] [Related]
19. Studies of fibrinogen binding to porcine platelets by flow cytometry: a method for studies of porcine platelet activation.
Larsson A; Eriksson M; Lindahl TL
Platelets; 2002 May; 13(3):153-7. PubMed ID: 12180497
[TBL] [Abstract][Full Text] [Related]
20. Ristocetin- and thrombin-induced platelet aggregation at physiological shear rates: differential roles for GPIb and GPIIb-IIIa receptor.
Kasirer-Friede A; Frojmovic MM
Thromb Haemost; 1998 Sep; 80(3):428-36. PubMed ID: 9759623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
